A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin
Part of paid clinical trials in Little Rock, Arkansas.
- Sponsor
- AstraZeneca
- Study ID
- NCT07664553
- Phase
- PHASE3
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Elecoglipron — DRUGElecoglipron is administered orally once daily.
- Placebo — DRUGPlacebo is administered orally once daily.
Study Details
The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron compared with placebo in adults with Type 2 Diabetes Mellitus (T2DM), treated with a background insulin and other background glucose-lowering medication(s)
Key Dates
- First listed
- Jun 24, 2026
- Start date
- Jul 8, 2026
- Status verified
- Jul 2026
- Primary completion
- May 23, 2028
- Completion
- May 23, 2028
Study Design
- Enrollment
- 600 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Elecoglipron dose level 1Participants will receive elecoglipron at dose level 1 administered orally once daily.
- Experimental: Elecoglipron dose level 2Participants will receive elecoglipron at dose level 2 administered orally once daily.
- Placebo Comparator: PlaceboParticipants will receive placebo administered orally once daily.
Primary Outcome Measure
Change from baseline in Hemoglobin A1c (HbA1c) [ Time Frame: Baseline to Week 40 ]
Central Contacts
- AstraZeneca Clinical Study Information Center1-877-240-9479
Locations (17)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Research Site | Little Rock | Arkansas | 72205 | - |
| Research Site | Sacramento | California | 95821 | - |
| Research Site | Aurora | Colorado | 80045 | - |
| Research Site | DeLand | Florida | 32720 | - |
| Research Site | Doral | Florida | 33166 | - |
| Research Site | Ocoee | Florida | 34761 | - |
| Research Site | Decatur | Georgia | 30030 | - |
| Research Site | Potomac | Maryland | 20854 | - |
| Research Site | Brooklyn | New York | 11220 | - |
| Research Site | Cary | North Carolina | 27518 | - |
| Research Site | Morehead City | North Carolina | 28557 | - |
| Research Site | Myrtle Beach | South Carolina | 29572 | - |
| Research Site | Memphis | Tennessee | 38119 | - |
| Research Site | Houston | Texas | 77040 | - |
| Research Site | Round Rock | Texas | 78681 | - |
| Research Site | San Antonio | Texas | 78231 | - |
| Research Site | Renton | Washington | 98057 | - |
Find similar trials in Little Rock, AR
By condition
By specialty
Related Studies
- Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)Recruiting · Petter Bjornstad · Aurora, Colorado
- A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus.PHASE3 · Not Yet Recruiting · Oramed, Ltd. · Dallas, Texas
- Continued Access to the Endogenex System for Participants in the ReCET Pivotal StudyEnrolling By Invitation · Endogenex, Inc. · Miami, Florida
- A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 DiabetesPHASE3 · Recruiting · Hoffmann-La Roche · Guntersville, Alabama